Orthocell Limited (ASX:OCC)
Australia
· Delayed Price · Currency is AUD 1.015
+0.005 (0.49%)
Dec 5, 2025, 4:10 PM AEST
Orthocell Revenue
In the fiscal year ending June 30, 2025, Orthocell had annual revenue of 7.55M AUD with 42.05% growth. Orthocell had revenue of 5.15M in the half year ending June 30, 2025, with 51.51% growth.
Revenue
7.55M
Revenue Growth
+42.05%
P/S Ratio
36.44
Revenue / Employee
n/a
Employees
n/a
Market Cap
275.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.55M | 2.24M | 42.05% |
| Jun 30, 2024 | 5.32M | 1.07M | 25.27% |
| Jun 30, 2023 | 4.24M | 2.71M | 177.01% |
| Jun 30, 2022 | 1.53M | 513.76K | 50.47% |
| Jun 30, 2021 | 1.02M | 298.44K | 41.48% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.79B |
| Ansell | 3.06B |
| Telix Pharmaceuticals | 1.01B |
| Mesoblast | 26.23M |
Orthocell News
- 7 weeks ago - Perth biotech Orthocell targets US growth with $25m capital injection - The Australian Financial Review
- 1 year ago - Perth’s billionaire set is piling into this little-known medtech - The Australian Financial Review